Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/11732
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Coyle, D | - |
dc.contributor.author | Grunfeld, E | - |
dc.contributor.author | Coyle, K | - |
dc.contributor.author | Pond, G | - |
dc.contributor.author | Julian, JA | - |
dc.contributor.author | Levine, MN | - |
dc.date.accessioned | 2015-12-09T12:48:01Z | - |
dc.date.available | 2014-01-01 | - |
dc.date.available | 2015-12-09T12:48:01Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Journal of Oncology Practice, 10(2): pp. e86 - e92, (2014) | en_US |
dc.identifier.issn | 1554-7477 | - |
dc.identifier.issn | 1935-469X | - |
dc.identifier.uri | http://jop.ascopubs.org/content/10/2/e86 | - |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/11732 | - |
dc.description | This article is available to view on PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24326740 | en_US |
dc.description.abstract | Purpose: Survivorship care plans (SCPs) are recommended for patients who have completed primary treatment and are transitioning to routine follow-up care. However, SCPs may be costly, and their effectiveness is unproven. The study objective was to assess the cost effectiveness of an SCP for breast cancer survivors transitioning to routine follow-up care with their own primary care physician (PCP) using data from a recent randomized controlled trial (RCT). Methods: Resource use and utility data for 408 patients with breast cancer enrolled in the RCT comparing an SCP with standard care (no SCP) were used. The intervention group received a 30-minute educational session with a nurse and their SCP, and their PCPs received the SCP plus a full guideline on follow-up. Analysis assessed the societal costs and quality-adjusted life years (QALYs) for the intervention group and the control group over the 2-year follow-up of the RCT. Uncertainty concerning cost effectiveness was assessed through nonparametric bootstrapping and deterministic sensitivity analysis. Results: The no-SCP group had better outcomes than the SCP group: total costs per patient were lower for standard care (Canadian $698 v $765), and total QALYs were almost equivalent (1.42 for standard care v 1.41 for the SCP). The probability that the SCP was cost effective was 0.26 at a threshold value of a QALY of $50,000. A variety of sensitivity analyses did not change the conclusions of the analysis. Conclusion: This SCP would be costly to introduce and would not be a cost effective use of scarce health care resources. | en_US |
dc.description.sponsorship | Supported by Grant No. 17423 from the Canadian Breast Cancer Research Alliance. E.G. support by a clinician scientist award from the Ontario Institute for Cancer Res (OICR) through funding provided by the Government of Ontario. | en_US |
dc.format.extent | e86 - e92 | - |
dc.language.iso | en | en_US |
dc.publisher | The American Society of Clinical Oncology | en_US |
dc.subject | Survivorship care plans | en_US |
dc.subject | Breast cancer survivors | en_US |
dc.subject | Cost effectiveness | en_US |
dc.subject | Assessment | en_US |
dc.subject | Primary care physician | en_US |
dc.title | Cost effectiveness of a survivorship care plan for breast cancer survivors | en_US |
dc.type | Article | en_US |
dc.identifier.doi | http://dx.doi.org/10.1200/JOP.2013.001142 | - |
dc.relation.isPartOf | Journal of Oncology Practice | - |
pubs.issue | 2 | - |
pubs.publication-status | Published | - |
pubs.publication-status | Published | - |
pubs.volume | 10 | - |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
There are no files associated with this item.
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.